Wall Street analysts expect that Viewray Inc (NASDAQ:VRAY) will announce $29.68 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Viewray’s earnings, with the lowest sales estimate coming in at $29.55 million and the highest estimate coming in at $29.80 million. Viewray posted sales of $16.13 million during the same quarter last year, which suggests a positive year-over-year growth rate of 84%. The firm is expected to report its next quarterly earnings results on Thursday, March 15th.

On average, analysts expect that Viewray will report full year sales of $29.68 million for the current fiscal year, with estimates ranging from $43.67 million to $43.90 million. For the next fiscal year, analysts expect that the company will post sales of $88.79 million per share, with estimates ranging from $74.67 million to $102.90 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Viewray.

Viewray (NASDAQ:VRAY) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The firm had revenue of $12.20 million during the quarter, compared to analysts’ expectations of $18.63 million. The company’s quarterly revenue was up 2950.0% compared to the same quarter last year.

VRAY has been the topic of several research analyst reports. Mizuho reissued a “buy” rating and issued a $12.00 price objective on shares of Viewray in a research note on Wednesday, October 25th. BidaskClub cut Viewray from a “buy” rating to a “hold” rating in a research note on Saturday. Northland Securities reissued a “buy” rating and issued a $10.00 price objective on shares of Viewray in a research note on Friday, November 17th. Finally, ValuEngine cut Viewray from a “hold” rating to a “sell” rating in a research report on Friday, September 22nd. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $10.60.

Viewray (NASDAQ:VRAY) opened at $8.77 on Friday. Viewray has a 52 week low of $3.01 and a 52 week high of $10.39. The company has a quick ratio of 1.20, a current ratio of 1.59 and a debt-to-equity ratio of -1.67.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Pura Vida Investments LLC boosted its position in Viewray by 132.9% during the 3rd quarter. Pura Vida Investments LLC now owns 607,040 shares of the company’s stock valued at $3,497,000 after acquiring an additional 346,370 shares in the last quarter. Fosun International Ltd bought a new stake in Viewray during the 3rd quarter valued at $640,000. RTW Investments LP boosted its position in Viewray by 33.5% during the 3rd quarter. RTW Investments LP now owns 1,020,462 shares of the company’s stock valued at $5,878,000 after acquiring an additional 256,127 shares in the last quarter. Wells Fargo & Company MN boosted its position in Viewray by 95.9% during the 3rd quarter. Wells Fargo & Company MN now owns 37,802 shares of the company’s stock valued at $218,000 after acquiring an additional 18,502 shares in the last quarter. Finally, Citadel Advisors LLC bought a new stake in Viewray during the 3rd quarter valued at $174,000. 50.08% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “$29.68 Million in Sales Expected for Viewray Inc (VRAY) This Quarter” was published by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/10/29-68-million-in-sales-expected-for-viewray-inc-vray-this-quarter.html.

About Viewray

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Get a free copy of the Zacks research report on Viewray (VRAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viewray (NASDAQ:VRAY)

Receive News & Ratings for Viewray Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray Inc and related companies with MarketBeat.com's FREE daily email newsletter.